Pontmestrocel

普迈托赛

Report date: 2025/03/17 14:58:06

Base Information

Drug NamePontmestrocel
Drug Alias NameAutologous bone marrow-derived mesenchymal stem cells(Madison)人原始间充质干细胞（麦迪森）自体骨髓间充质干细胞疗法（麦迪森）HCD100HCD-100
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseHematologic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTianjin Madison Regenerative Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Madison Regenerative Medicine Co LtdMicro Life Technology Group Co Ltd
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseHematologic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A